Cormorant Asset Management, LP Avidity Biosciences, Inc. Transaction History
Cormorant Asset Management, LP
- $943 Million
- Q1 2025
A detailed history of Cormorant Asset Management, LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 400,000 shares of RNA stock, worth $11.9 Million. This represents 1.25% of its overall portfolio holdings.
Number of Shares
400,000
Previous 1,050,000
61.9%
Holding current value
$11.9 Million
Previous $30.5 Million
61.33%
% of portfolio
1.25%
Previous 2.41%
Shares
13 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$341 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$338 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$289 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$275 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$261 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.55B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...